Comparative Efficacy and Tolerability of Quetiapine XR and Amitriptyline in the Treatment of Fibromyalgia

• ClinicalTrials.gov Identifier: NCT00766350
• Recruitment Status: Completed
• First Posted: October 3, 2008
• Last Update Posted: December 3, 2014
• Sponsor: Universidad de Granada
• Collaborators: AstraZeneca; Hospital Clinico Universitario San Cecilio
• Information provided by (Responsible Party): Elena Pita Calandre, Universidad de Granada

Study Description

Brief Summary:

Quetiapine, a second generation antipsychotic, has shown beneficial activity on fibromyalgia symptomatology, administered as add-on treatment, in a sample of 35 patients. The purpose of the present study is to compare, in a controlled setting, the efficacy and the tolerability of quetiapine extended release with amitriptyline in the treatment of patients with fibromyalgia

Condition or disease	Intervention/treatment	Phase
Fibromyalgia	Drug: amitriptyline; Drug: quetiapine	Phase 4

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Pilot Clinical Trial to Assess the Comparative Efficacy and Tolerability of Quetiapine XR Versus Amitriptyline for the Treatment of Patients With Fibromyalgia
• Study Start Date: November 2008
• Actual Primary Completion Date: March 2010
• Actual Study Completion Date: October 2010

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: amitriptyline	Drug: amitriptyline; initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks; Other Name: Tryptizol
Experimental: quetiapine	Drug: quetiapine; initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks; Other Name: Seroquel XR

Outcome Measures

Primary Outcome Measures :

1. Mean change from baseline to endpoint in the total score of Fibromyalgia Impact Questionnaire [ Time Frame: baseline, 4, 8, 12 and 16 weeks ]

Secondary Outcome Measures :

1. Change from baseline to endpoint in the scores of the Brief Pain Inventory, the Pittsburgh Sleep Quality Inventory, the Beck Depression Inventory, and the State and Trait Anxiety Inventory [ Time Frame: baseline, 4, 8, 12 and 16 weeks ]
2. Discontinuation rates due to treatment-related adverse events, proportion of patients experiencing adverse events, proportion of patients experiencing serious adverse events, adverse events description and classification. [ Time Frame: baseline, 0, 4, 8, 12 and 16 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female patients aged 18 70 years.
2. Meeting American College of Rheumatology criteria for primary fibromyalgia: widespread aching pain in all four quadrants of the body and axial skeleton and greater than or equal to 11 of 18 tender points under digital palpation examination.
3. A FIQ total score (0 100) of 40 or greater
4. A score of 4 or greater on the average pain item of the BPI
5. Written informed consent
6. Female patients of childbearing potential must be using a reliable contraceptive method and have a negative urine human chorionic gonadotropin (HCG) test at enrolment.
7. Able to understand and comply with the requirements of the study.

Exclusion Criteria:

1. Evidence of current traumatic injury, inflammatory rheumatic disease, or infectious or endocrine related joint disease.
2. A lifetime history of hypomania, mania, psychosis or dementia.
3. Current primary Axis I diagnosis other than major depressive disorder
4. Substance or alcohol dependence at enrolment and within the past 12 months (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM IV
5. Severe depression as evidenced by a Beck Depression Inventory score ≥ 30
6. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
7. History of seizures
8. Known lack of response to 2, or more than 2, different type of antidepressants in depression of fibromyalgia.
9. Pregnancy or breast feeding.
10. Patients with a history of urinary retention, angle closure glaucoma, or increased intraocular pressure.
11. Patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease or conditions which would predispose patients to severe hypotension (dehydration, hypovolemia and treatment with antihypertensive medications).
12. Patients who have received IMAOs, SSRIs or other antidepressants within two weeks of randomization.
13. Current or past history of kidney or liver insufficiency
14. Prior to randomization. Unwillingness to discontinue previously prescribed drugs for fibromyalgia other than those authorized in the protocol, as acetaminophen and bromazepam
15. Patients who have received quetiapine or amitriptyline within 1 year of randomization.
16. Patients with known intolerance or lack of response to quetiapine fumarate and/or amitriptyline, as judged by the investigator
17. Use of any of the following cytochrome P450 3A4 inhibitors within 14 days of enrolment, including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine, and saquinavir
18. Use of any of the following cytochrome P450 inducers within 14 days of enrolment, including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's wort, and glucocorticoids
19. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM IV criteria within 4 weeks of enrolment
20. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment, with clinical relevance.
21. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension), as judged by the investigator
22. Involvement in planning and conduct of the study
23. Previous enrolments or randomisation of treatment in the present study.
24. Participation in another trial with drugs within 4 weeks of enrolment into this study or a longer period in accordance with local requirements.
25. Patients with uncontrolled Diabetes Mellitus (DM)
26. An absolute neutrophil count (ANC) equal or lower than 1.5 x 109 per liter.
27. Patients who show at the randomization visit a reduction in the FIQ total score equal or greater than 20% from the screening visit.

Contacts and Locations

Locations

Spain

Hospital Clinico Universitario San Cecilio

Granada, Spain, 18012

Sponsors and Collaborators

Universidad de Granada

AstraZeneca

Hospital Clinico Universitario San Cecilio

Investigators

• Principal Investigator: Elena P Calandre, MD; Clinical Pharmacology Department of the Hospital Clinico Universitario San Cecilio

More Information

Publications:

Hidalgo J, Rico-Villademoros F, Calandre EP. An open-label study of quetiapine in the treatment of fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):71-7. Epub 2006 Aug 4.

• Responsible Party: Elena Pita Calandre, Professor of Pharmacology, Universidad de Granada
• ClinicalTrials.gov Identifier: NCT00766350
• Other Study ID Numbers: D1443C00024
• First Posted: October 3, 2008
• Last Update Posted: December 3, 2014
• Last Verified: December 2014

Keywords provided by Elena Pita Calandre, Universidad de Granada:

fibromyalgia; quetiapine; amitriptyline

Additional relevant MeSH terms:

Fibromyalgia; Myofascial Pain Syndromes; Muscular Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Neuromuscular Diseases; Nervous System Diseases; Amitriptyline; Quetiapine Fumarate; Amitriptyline, perphenazine drug combination; Antidepressive Agents; Psychotropic Drugs; Antipsychotic Agents; Tranquilizing Agents; Central Nervous System Depressants; Physiological Effects of Drugs; Antidepressive Agents, Tricyclic; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Adrenergic Uptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Adrenergic Agents; Neurotransmitter Agents